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Abstract
Background: Accurate risk (penetrance) estimates for associated phenotypes in carriers of a major disease gene are important
for genetic counselling of at-risk individuals. Population-specific estimates of penetrance are often needed as well. Families
ascertained from high-risk disease clinics provide substantial data to estimate penetrance of a disease gene, but these estimates
must be adjusted for possible specific sources of bias.
Methods: A cohort of 12 independently ascertained HNPCC families harbouring a founder MSH2 mutation was identified from
a cancer genetics clinic in St. John's, Newfoundland, Canada. Carrier status was known for 247 family members but phenotype
information on up to 85 additional relatives with unknown carrier status was available; using modified segregation models these
additional individuals could be included in the analyses. Three HNPCC-related phenotypes were evaluated as age at diagnosis
of: any HNPCC cancer (first cancer), colorectal cancer (CRC), and endometrial cancer (EC) for females.
Results: Lifetime (age 70) risk estimates for male and female carriers were similar for developing any HNPCC cancer (Males =
98.2%, 95% Confidence Interval (CI) = (93.8%, 99.9%); Females = 92.8%, 95% CI = (82.4%, 99.1%)) but female carriers
experienced substantially reduced lifetime risk for developing CRC compared to male carriers (Females = 38.9%, 95% CI =
(24.2%, 62.1%); Males = 84.5%, 95% CI = (67.3%, 91.3%)). Female non-carriers had very low lifetime risk for these two outcomes
while male non-carriers had lifetime risks intermediate to the female carriers and non-carriers. Female carriers had a lifetime
risk of developing EC of 82.4%. Relative risks for developing any HNPCC cancer (carriers relative to non-carriers) were
substantially greater for females compared to their male counterparts (Females = 54.8, 95%CI = (4.4, 379.8); Males = 9.7, 95%
CI = (0.3, 23.8)). Relative risks for developing CRC at age 70 were substantially greater for females compared to their male
counterparts (Females = 23.7, 95%CI = (5.6, 137.9); Males = 6.8%, 95% CI = (2.3, 66.2)). However, the risk of developing CRC
decreased with age among both genders.
Conclusion: The proposed modified segregation-based models used to estimate age-specific risks for HNPCC phenotypes can
reduce bias due to ascertainment and missing genotype information as well as provide estimates of absolute and relative risks.
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Background
Extensive knowledge about Mendelian disease genes is
accumulating as more are discovered, characterized and
studied in high risk families. With this accumulating
knowledge comes the opportunity for carriers to have
improved surveillance and treatment options so disease is
detected at an early stage and adverse outcomes are
reduced. However, accurate age-and sex-specific pene-
trance estimates are critical for genetic counseling of at-
risk individuals in order to establish and evaluate disease
control efforts. For instance, risk models have recently
been developed to predict germline mutations linked to
Lynch syndrome (hereditary nonpolyposis colorectal can-
cer or HNPCC) but unlike existing models, these models
require a prior specification of the penetrance function to
give accurate predictions [1-3].
HNPCC is an example of an autosomal dominant Mende-
lian disease which has seen remarkable improvements in
associated morbidity and mortality in recent years due to
early identification, surveillance and treatment of gene
carriers [4,5]. It is caused by a mutation in one of the mis-
match repair genes: MLH1, MSH2, MSH6 or PMS2 and
accounts for about 3% of all colorectal cancer (CRC) cases
[6]. Carriers of one of these mutations are at increased life-
time risk of developing cancers of the colon,
endometrium, ovary, stomach, ureter, upper biliary tract,
skin, and brain [7,8]. Early age at onset is another hall-
mark of this syndrome.
Studies of heritable genetic diseases are often conducted
using families with multiple affected individuals since
high risk alleles are often rare in the general population.
However, families identified through high risk disease
clinics tend to be more likely to carry the disease gene
mutation and to have phenotype information, compared
to pedigrees identified through population-based sam-
pling of affected probands. Thus, families identified in
clinic-based designs may not be representative of the pop-
ulation and ascertainment may be biased to multiple case
families. In addition to ascertainment issues, missing gen-
otype information can be problematic in these pedigrees.
Genetic testing may not be offered to all family members
based on an individual's risk of carrying the deleterious
allele and some family members may have already died
without testing. Still others may decline testing.
Statistical models based on segregation methods have
been developed which can estimate age-specific pene-
trance in these high risk families and can adjust for ascer-
tainment bias and missing genotype data. Traditionally,
segregation-based methods have been used to fit genetic
models to phenotype data collected from pedigrees. These
methods can easily adjust for complex ascertainment
when the rules of sequential sampling of pedigrees are fol-
lowed, infer the missing genotypes using family structure
and evaluate whether another segregating gene might be
involved [9,10]. More precise estimates and confidence
intervals (CIs) can be obtained with these methods com-
pared to standard methods, since additional genotyped
individuals are included. When the form of the disease
risk (e.g., risk increasing or decreasing with age or both)
could vary for different age-at-onset phenotypes, a general
formulation of the hazard function is necessary.
This paper addresses these key challenges in disease risk
estimation by using new statistical methods in a study of
12 HNPCC families, who were ascertained at a New-
foundland (NL) cancer genetics clinic and who share a
founder MSH2 mutation. In Newfoundland, founder
mutations causing autosomal dominant disease, large
family sizes over 8-10 generations and little in or out
migration since the founding settlements in the late 18th
and early 19th centuries [11] have enabled discoveries of
phenotype - genotype correlations in right arrhyth-
mogenic ventricular cardiomyopathy, [12] autosomal
dominant polycystic kidney disease, [13] and HNPCC
[14]. These NL families share common lifestyle and/or
environmental factors which makes them well-suited for
genetic studies of risk estimation. However, their isolation
and development might mean that risk estimates from
other populations may not be appropriate for them as
other risk factors in addition to the founder mutation may
affect the rates of penetrance [15-18].
Methods
Family ascertainment and characteristics
Twelve families with hereditary CRC were independently
identified from the Medical Genetics Clinic at Memorial
University, St. John's, NL, Canada, and were confirmed as
carrying the MSH2 mutation A → T nt942+3. Based on
their geographic proximity in an isolated area of the prov-
ince, as well as having common haplotypes of a subset of
at least five microsatellite markers, it is assumed these
families have a common ancestor. See Green et al. (2002)
for additional details [7]. Data collected from these fami-
lies have been updated since that initial report, including
additional HNPCC outcomes and genotyping of family
members.
DNA testing for the MSH2 mutation identified individu-
als as carriers or non-carriers. For those not tested, clini-
cally presumed (including obligate) carriers for any
HNPCC were evaluated using Bayes-Mendel [19]. Using a
carrier probability threshold of 0.95, 36 presumed carriers
were identified as carriers. All other individuals were con-
sidered to have unknown mutation status.Hereditary Cancer in Clinical Practice 2009, 7:16 http://www.hccpjournal.com/content/7/1/16
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Statistical Methods
The clinical outcomes of interest (phenotypes) in this
study were age to diagnosis of CRC, age to diagnosis of
first HNPCC cancer (included CRC, small bowel,
endometrium, ovary, gastric, urinary tract, brain, and bile
duct), and among the females, age to diagnosis of
endometrial cancer (EC). Lifetime risk or penetrance at
age 70 for these three outcomes is of particular interest.
Observations on participants were censored at their age at
last followup if no phenotypes were observed; after enter-
ing a screening program; or for age to diagnosis of EC for
females, after having a hysterectomy/oophorectomy for
non-cancer reasons.
The Kaplan-Meier (KM) estimator is often used to esti-
mate age-specific penetrance but has known limitations
[20]. Although it is robust to the correlation in outcomes
among family members, it does not correct for ascertain-
ment bias associated with these high risk families or infer
missing genotype information.
Modified segregation-based methods can account for the
non-random ascertainment of families as well as missing
genotype information [9,10,21]. We considered a general
parametric form for the hazard function, which adopted a
Weibull baseline hazard function. The generalized log-
Burr hazard form (see Additional file 1) includes the
standard Weibull proportional hazards model or the log-
logistic model as special cases [22]. The Weibull model is
quite flexible but does have a monotonic functional form
of the hazard whereas the log-logistic specification does
not. As Jenkins et al. (2006) found, risk can increase and
then decrease with age, so assuming monotonicity for risk
may not always be appropriate [23]. With three clinical
phenotypes of interest, the general formulation permits
appropriate functional form choices for each outcome.
Likelihood ratio statistics were used to select a simpler
model (i.e., either Weibull or log-logistic) that was com-
patible with the general model [24]. All regression models
included the variables for sex and genotype status and
their interaction.
Stratified risk estimates were calculated by sex and by
mutation status for each phenotype and the correspond-
ing 95% confidence intervals were calculated by simula-
tion. Specifically, 1,000 parameters sets were simulated,
assuming a multivariate normal distribution for the esti-
mated parameters. The 95% CI for the cumulative risk to
a specific age (range 20-70 years) was estimated as the
region between the 2.5th and 97.5th percentiles of the dis-
tribution obtained by substituting the sets of simulated
parameters into the penetrance function [23].
To correct penetrance estimates for families ascertained
through an individual with cancer who also satisfied high
or intermediate familial risks, we used an ascertainment-
corrected retrospective (ACR) likelihood approach (see
Additional file 2) [25-27]. Correction was based on the
conditional probability of the observed genotypes in the
first degree relatives of the carrier proband, given the
observed presence or absence of disease in each person,
and corrected for the ascertainment event (i.e. the diagno-
sis of cancer in the proband) which caused the family to
be sampled [9,10,25]. We obtained the maximum likeli-
hood estimates of the needed parameters by maximizing
this ACR likelihood and then used the parameters to esti-
mate age-specific cumulative and relative risks for each
outcome, using the penetrance function in equation (2)
of Additional file 1[9,10]. These modified segregation
methods based on an ACR likelihood were implemented
in the genetic software program, Mendel [28].
Results and Discussion
Description of Family Data Set
The number of family members with phenotype informa-
tion varied from 146 (EC) to 313 (any HN-PCC cancer) to
332 (CRC), with 122 males and 125 females having
known genotypes (see Table 1). However, family mem-
bers with unknown mutation status often had a substan-
tial number of outcomes. For instance, 15 of the 43 males
with unknown carrier status were diagnosed with having
any HNPCC cancer. Excluding these family members who
were not genotyped and were not presumed carriers will
impact the risk estimates.
Modified Segregation-based Methods
The general formulation for the hazard function (shown
in Additional file 1 and which included the interaction
term) yielded these findings:
• Any HNPCC cancer: log-likelihood value was -617.3
and   was 13831,
￿ CRC: log-likelihood value was -479.1 and   was
0.96,
￿ EC: log-likelihood value was -283.4 and   was 0.2.
These results suggest that different models are appropriate
for each phenotype. Likelihood ratio test statistics con-
firmed that the general model formulation was consistent
with these specific parametric forms: the Weibull model
for any HNPCC cancer (p-value = 1.0, log-logistic model
had p-value of 0.03), and the log-logistic model for CRC
(p-value = 0.40, Weibull model had p-value of 0.11, but
had a larger log likelihood value). The log-logistic model
was used for EC (p-value = 0.03), as the general model did
not converge.
ˆ q
ˆ q
ˆ qHereditary Cancer in Clinical Practice 2009, 7:16 http://www.hccpjournal.com/content/7/1/16
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Based on these selected models for each phenotype, we
estimated the penetrance functions using the correspond-
ing parameter estimates. The estimated penetrance func-
tions, stratified by sex and mutation status, are displayed
in Figure 1. The age-related risk of developing any HNPCC
cancer for carriers increases quickly after age 30, with
females experiencing slightly lower risks than males over
their lifetimes. Male non-carriers also experience slightly
greater lifetime risk than the female non-carriers with dif-
ferences appearing past age 40.
Cumulative risk for CRC was not surprisingly highest for
males, compared to their female counterparts. For
instance, lifetime CRC risk estimates for male carriers was
84.5% (95% CI = (67.3%, 91.3%)) whereas for female
carriers it was 38.9% (95% CI = (24.2%, 62.1%)). The
95% CIs drawn at ages 30, 50 and 70 reveal that male car-
riers have significantly higher plausible values than
female carriers, but there is no difference between genders
among the non-carriers. Table 2 provides the point and
95% CI estimates of the penetrance for any HNPCC can-
cer, CRC and EC at ages 30, 50 and 70 (lifetime risk).
Endometrial cancer results reveal a relatively low cumula-
tive risk to age 30 (0.7%) for female carriers which rises
sharply to 82.4% by age 70. For non-carriers, risk was
essentially zero throughout the women's lifetimes. The
low number of women diagnosed with EC meant confi-
dence intervals could not be estimated.
In addition to the absolute risk estimates obtained with
the modified segregation analyses, the relative risks (RR)
for developing any HNPCC cancer and CRC were also cal-
culated (Equation 2, Additional file 1). Table 3 presents
the risks for carriers relative to non-carriers, stratified by
sex. For age at onset of any HNPCC cancer, the Weibull
model was again adopted so the RR are automatically con-
stant with respect to age. The interaction between carrier
status and sex was not significant in this model. Although
males had higher absolute risks compared to females
regardless of carrier class, female carriers had more than
five times the relative risks (54.8), compared to male car-
riers (9.7). The very wide 95% CI for the female carriers
(4.4, 379.8), however, suggests a lack of precision; it also
overlaps with the corresponding ones for the male carriers
(0.3, 23.8) indicating no statistically significant difference
between them. The scant number of events in female non-
carriers meant RR estimates for EC were not estimable.
For age at onset of CRC, the log-logistic model was
adopted so risks could vary with age. Overall, the risk for
female carriers relative to female non-carriers was higher
than for male carriers relative to male non-carriers over
the entire age range considered. At age 30, the RR for male
carriers, 34.1 (95% CI = (7.1, 167.0)) was nearly the same
as for female carriers, 37.7 (95% CI = (7.5, 176.9)). But by
age 70, the relative risk for male carriers (6.8, 95% CI =
(2.3, 66.2)) was one third the relative risk for female car-
riers (23.7, 95% CI = (5.6, 137.9)). Thus, female carriers
had greater relative risks of developing CRC compared to
their male counterparts through out their adult lifetimes
although their 95% CIs did overlap. This risk difference
became substantial by age 70.
Discussion
Our paper confirmed the relatively high penetrance asso-
ciated with MSH2 gene mutations in these NL HNPCC
families for various phenotypes, including CRC. Several
studies have previously evaluated the risk of developing
CRC among identified MMR gene mutation carriers in
HNPCC families, where the risk to age 70 ranged from
22% to 100% [7,15-18,29-36]. Some studies suggested
different risks associated with MLH1 and MSH2 [16,31]
while others reported males having nearly twice the risk of
Table 1: Description of NL Family Data Set.
Group Any HNPCC† cancer CRC‡ ECΔ
Events n Events n Events n
Males
Carriers* 34 71 32 71 - -
Non-carriers 2 51 1 51 - -
Unknowns 15 43 9 53 - -
Females
Carriers* 38 74 16 74 16 73
Non-carriers 1 51 0 51 0 51
Unknowns 9 23 4 32 1 22
Family Members with Phenotype Information 313 332 146
Number of each phenotype per subgroup based on sex and mutation status
* includes known carriers and presumed carriers, n = number of relatives
† HNPCC = hereditary nonpolyposis colorectal cancer
‡ CRC = colorectal cancer, Δ EC = endometrial cancerHereditary Cancer in Clinical Practice 2009, 7:16 http://www.hccpjournal.com/content/7/1/16
Page 5 of 9
(page number not for citation purposes)
Segregation model estimates of penetrance for any HNPCC, CRC and EC Figure 1
Segregation model estimates of penetrance for any HNPCC, CRC and EC. Age-specific cumulative risks and 95% 
confidence intervals of hereditary nonpolyposis colorectal cancer related cancers [(a) any hereditary nonpolyposis colorectal 
cancer, (b) colorectal cancer, (c) endometrial cancer] among mutation carriers and non-carriers specified by gender, based on 
the segregation analyses.
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females [15,16,18]; these differences were not consistent
across studies. The lower penetrance reported among
females suggests they are somehow protected from CRC,
perhaps due to environmental/reproductive factors
unique to women or to a sex-linked modifier gene. How-
ever, not all of these studies adjusted for ascertainment,
nor adopted the same statistical methods of penetrance
function estimation.
Our study confirmed a gender-specific effect on the risk of
developing CRC with a higher lifetime risk in males than
females (84.5% vs. 38.9% by age 70). These high risks
could be due to the specific founder mutation effect,
shared environment and limited screening for many of
the older family members. Our study also underlined the
relative importance of other cancers in these large New-
foundland families. Women are susceptible to developing
endometrial cancer with a penetrance close to 82.4% by
age 70 and when considering all HNPCC-related cancers,
the lifetime risks in males and females carriers were simi-
larly very high, 98.2% and 92.8%, respectively. Interest-
ingly, our study also showed that the relative effect of
MSH2 on CRC for males and females combined as meas-
ured by the hazard ratio, decreases with age (from 43.1 at
age 30 to 16.9 at age 70, results not shown). Such an effect
was also suggested in Jenkins et al. [23] and in a very
recent study from Ontario [9].
To illustrate the importance of having specific penetrance
estimates for the HNPCC families in Newfoundland (NL),
we estimated both the probability of being a MSH2 muta-
tion carrier and the probability of developing CRC and EC
in cancer-free individuals in Family 1 from our sample.
These probabilities can be computed for any family mem-
ber, i.e. the counselee, and are conditional on the
observed phenotypes and genotypes in the family. Gen-
der- and age-specific penetrance are used to derive a pos-
terior probability of being a mutation carrier and then the
Table 2: Penetrance and 95% Confidence Interval Estimates.
Group Age 30 (95% CI) Age 50 (95% CI) Age 70 (95% CI)
Any HNPCC cancer (Weibull)
Male Carrier 9.1 (6.0, 17.9) 70.5 (59.1, 87.7) 98.2 (93.8, 99.9)
Female Carrier 6.1 (3.8, 11.6) 55.3 (42.8, 73.1) 92.8 (82.4, 99.1)
Male Non-carrier 1.0 (0.0, 1.6) 11.9 (0.2, 20.0) 33.9 (0.5, 53.6)
Female Non-carrier 0.1 (0.0, 1.4) 1.5 (0.1, 18.2) 4.7 (0.4, 49.8)
CRC (Log-logistic)
Male Carrier 11.1 (3.9, 19.9) 62.2 (38.4, 73.8) 84.5 (67.3, 91.3)
Female Carrier 1.4 (0.6, 3.7) 16.1 (8.9, 30.5) 38.9 (24.2, 62.1)
Male Non-carrier 0.3 (0.0, 1.6) 4.1 (0.6, 16.2) 12.5 (2.0, 39.8)
Female Non-carrier 0.0 (0.0, 0.3) 0.5 (0.1, 2.9) 1.6 (0.3, 9.3)
EC (Log-logistic)
Female Carriers 0.7 37.1 82.4
Female Non-carriers 0.0 0.0 0.0
Penetrance estimates (percent) at ages 30, 50 and 70 by carrier status and sex, with corresponding 95% confidence intervals. Estimates based on 
the specified hazard function for age at diagnosis of any hereditary nonpolyposis colorectal cancer (any HNPCC cancer), colorectal cancer (CRC) 
and endometrial cancer (EC)
Table 3: Hazard Ratio and 95% Confidence Interval Estimates.
Group Age 30 (95% CI) Age 50 (95% CI) Age 70 (95% CI)
Any HNPCC cancer (Weibull)
Male 9.7 (0.3, 23.8) 9.7 (0.3, 23.8) 9.7 (0.3, 23.8)
Female 54.8 (4.4, 379.8) 54.8 (4.4, 379.8) 54.8 (4.4, 379.8)
CRC (Log logistic)
Male 34.1 (7.1, 167.0) 15.1 (3.9, 110.2) 6.8 (2.3, 66.2)
Female 37.7 (7.5, 176.9) 32.2 (6.9, 162.1) 23.7 (5.6, 137.9)
Hazard ratio estimates at ages 30, 50 and 70 in mutation carriers compared with mutation non-carriers by sex, with corresponding 95% confidence 
intervals. Estimates based on the specified hazard function for age at diagnosis of any hereditary nonpolyposis colorectal cancer and colorectal 
cancer
HNPCC = hereditary nonpolyposis colorectal cancer
CRC = colorectal cancerHereditary Cancer in Clinical Practice 2009, 7:16 http://www.hccpjournal.com/content/7/1/16
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disease risk estimate is calculated as a weighted average
over the mutation status, where the weights are the muta-
tion carrier probabilities [19]. Computations were carried
out using the package MMRpro in the R library BayesMen-
del [19]. We compared the probability of being a muta-
tion carrier and of developing the two outcomes for a
selected counselee using either publically available pene-
trance estimates for MSH2 [1] or the penetrance estimates
obtained from our own analyses of the NL family data set.
We chose individual 48 in family 1 as the counselee (see
Figure 2). This is a woman who is cancer free to age 48 and
is a mutation carrier. Her mother (the proband in the fam-
ily) had an endometrial cancer (EC) at age 47 and a color-
ectal cancer (CRC) at age 67 and was a confirmed
mutation carrier. First, we ignore the counselee's mutation
status. Assuming a mutation prevalence varying from
0.1% to 1% in the Newfoundland population, the carrier
probability for the counselee ranged from 37% to 41%
when using our derived penetrance estimates and was
similar to the value of 43% obtained from using the pub-
lished estimates. The probability of developing CRC and
EC by age 83 for this person was 18% and 28%, respec-
tively, when using our penetrance estimates and 12% and
19%, respectively, when using the published estimates.
Next, we assumed the couselee's mutation status is
known. The probability of developing CRC and EC by age
83 was 42% and 70%, respectively, when using our pene-
trance estimates but only 22% and 40%, respectively,
when using the published penetrance estimates. These
risk estimates were not sensitive to the mutation preva-
lence. Thus, using our calculated penetrance values, we
found both the carrier probability and development of
both phenotypes differed from values obtained using
published data from other populations.
Our paper also demonstrates the strength of the modified
segregation-based analysis to estimate the penetrance of
HNPCC-related cancers in these large Newfoundland
families. First, unlike the classical Kaplan-Meier estimator,
this approach can infer missing genotypes by using the
Mendelian transmission probabilities and genealogical
relationships. As a consequence, the segregation-based
analysis was able to use information on up to 85 addi-
tional relatives, resulting in more precise and potentially
less biased penetrance estimates. Second, the modified
segregation-based analysis can correct for ascertainment
when families were recruited through several affected
individuals. Our recent simulation studies [9] have shown
that the inference through the retrospective ascertain-
ment-corrected likelihood approach that we proposed
was nearly unbiased for various types of family-based
designs (population-and clinic-based) and genetic mod-
els (including one-and two-gene models). Finally, segre-
gation-based methods allow several parametric hazard
functions to be considered. We proposed a generalized
log-Burr formulation of this function, which includes the
Weibull or log-logistic forms as particular cases, so a better
fit of the cumulative risk function results.
For the aforementioned reasons, our results differ some-
what from those published by Green et al. [7] who used
the Kaplan-Meier estimator on an earlier version of the
data. For example, their penetrance estimates for CRC
were 92% and 64% by age 70 in males and female carriers,
respectively, compared to 85% and 39% in our study. The
main difference is likely from our use of an ascertainment
correction [25]. In addition, Green et al. (2002) combined
the relatives with unknown genotypes with the non-carri-
ers, whereas our approach used a weighted average over
the missing data.
Our results also differ from those of Quehenberger et al.
(2005), Barrow et al. (2008) and Alarcon et al. (2007),
even though these three studies also adjusted for ascer-
tainment of high-risk families and missing genotype
information [33,35,36]. Several important differences
might explain the lower risk estimates these authors
found in their data. Although all of these other studies
had substantially more confirmed carrier families for the
phenotypes they considered (CRC, and possibly EC and
Minor HNPCC site), they ended up combining families
segregating different DNA mismatch repair (MMR) alleles
together. They also had proportionally more missing gen-
otype information in the MSH2 families than the 34% in
our data: 68.3% in Quehenberger et al. (2005), 41 to 76%
Family 1 Figure 2
Family 1. Pedigree illustrating need for population-specific 
probabilities of being a MSH2 mutation carrier and the prob-
ability of developing CRC and EC in cancer-free individuals in 
Family 1 from our sample.Hereditary Cancer in Clinical Practice 2009, 7:16 http://www.hccpjournal.com/content/7/1/16
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in Barrow et al. (depending on whether one includes the
putative and assumed carriers as known) and 84% in Alar-
con et al. (in the combined MLH1 and MSH2 families).
All of the families in these other studies of non-island
populations likely did not share the same founder muta-
tion, as was the case in the NL data.
In addition to the differing study populations, pooling
across MMR genes and varying proportions of genotyped
family members, methodological differences might also
be impacting the penetrance estimates. Quehenberger et
al. and Alarcon et al. assumed a fixed population allele fre-
quency and adopted their national (Netherlands or
France) cancer incidence rates for the noncarriers rather
than estimating it. Modelling differences between these
studies and this one included the use of polynomial func-
tions assuming competing risks (Quehenberger et al.), a
genotype restricted likelihood method that employed a
Weibull distribution (Alarcon et al.), and the Kaplan-
Meier nonparametric estimator (Barrow et al.).
The competing risk model estimates, in particular, are
affected by the rates of all phenotypes under considera-
tion, which are also likely not independent for HNPCC
cancers. Absolute risk estimates for the time to first
HNPCC cancer from our study (Table 2, first two rows)
can be compared to Quehenberger et al. combined (CRC
+ EC +MC) age dependent cause specific cumulative risks
(Table four, second section, last two columns): our risk
estimates at ages 30, 50 and 70 years are consistently
higher for both male and female carriers although both
approaches had wide 95% confidence intervals. Relative
risks for time to first CRC (Table 3 in both studies) suggest
decreasing risk over lifetimes, with our study estimating a
wider range of values and different values for males and
females. Our absolute lifetime risk estimates for time to
CRC from our study can be compared to those of Barrow
et al. (Table four, rows 2 and 4, column 70-79 years): our
risk estimates at age 70 years are higher for male MSH2
carriers but lower for female carriers and our 95% confi-
dence intervals substantially wider. When we compare our
estimates of time to CRC with the results obtained by
Alarcon et al. (Figure 2, combined MSH2 and MLH1 fam-
ilies), our risk estimates at ages 30, 50 and 70 years are
consistently higher for both male and female carriers but
the wide 95% confidence intervals do overlap for each
gender. Estimates of time to EC are also much higher in
our study than in the Alarcon et al. one, although both
found very little risk until age 30.
Conclusion
In summary, the risk estimates we obtained using a mod-
ified segregation approach within a general hazard frame-
work are adjusted for ascertainment of the family
members and are able to include those family members
with missing genotype information. Thus, this novel and
flexible approach reduces several sources of bias in the
penetrance estimates for HNPCC-related phenotypes.
However, the most appropriate ascertainment adjustment
and method for dealing with missing genotype informa-
tion for penetrance estimation is an open problem.
Although many sources of bias have been reduced in this
study, several limitations may still exist. First, the sample
size is relatively small for a risk estimation study and the
confidence intervals were often wide, especially for esti-
mating gender-specific penetrances. This problem was
only partly overcome by using the modified segregation-
based approach. Second, inaccuracy of cancer diagnosis or
screening history might introduce error because some
cases or dates of entry into screening programs could not
be confirmed. Further work on the impact of screening is
warranted. Lastly, we did not adjust our analysis for com-
peting risks nor try to model specifically the correlation
between the different HNPCC-related cancers or other
sources of familial correlation besides the MSH2 muta-
tion. Phenotypic heterogeneity and multiple phenotypes
also pose challenges. We are planning to investigate these
issues in some future work.
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